| EMR |
Report |
Adjusted operating EPS |
IN-LINE |
pred ~$1.69 vs. cons $1.6767 |
MEDIUM |
| EMR |
Report |
Net sales |
IN-LINE |
pred ~$4.83B vs. cons $4.801B |
MEDIUM |
| EMR |
Report |
Underlying sales growth |
BEAT |
pred ~4.9% vs. cons 4.75% |
MEDIUM |
| EMR |
Guide |
4Q26 adjusted EPS |
UNCHANGED |
guide ~$1.79-$1.84 vs. cons $1.8266 |
LOW |
| EMR |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide $6.45-$6.55 vs. cons $6.5025 |
MEDIUM |
| EMR |
Guide |
FY26 underlying sales growth |
UNCHANGED |
guide ~3% vs. cons 3.03% |
MEDIUM |
| EMR |
Guide |
Orders / backlog commentary |
UNCHANGED |
guide mid-single-digit orders, backlog supports 2H |
MEDIUM |
| EMR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
LOW |
| EMR |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintain is insufficient for the setup |
LOW |